2026-04-20 FDA Warning Letter: Wellmill, LLC dba Vitamix Laboratories Cited for Juice HACCP/CGMP for Foods/Adulterated/Insanitary Conditions
Letter issued · posted to fda.gov .
Subject as published: Juice HACCP/CGMP for Foods/Adulterated/Insanitary Conditions
TL;DR
In short: On April 20, 2026, the FDA's Human Foods Program issued a Warning Letter to Wellmill, LLC dba Vitamix Laboratories (Nesconset, NY) following a December 3-12, 2025 inspection, citing serious violations of the Juice HACCP regulation (21 CFR Part 120) and determining that the firm's juice products are adulterated under section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act due to preparation under insanitary conditions. The FDA found that the facility failed to conduct adequate hazard analysis or implement a written HACCP plan for juice products blended with probiotic ingredients under non-aseptic, ambient conditions without subsequent pathogen reduction, creating reasonably likely biological hazards (environmental contamination with Salmonella, E. coli O157:H7, Listeria monocytogenes; bacterial growth from time/temperature abuse at pH >4.0) and physical hazards (glass fragments), and lacked documented room temperature controls during blending and holding operations.
Argus analysis
# FDA Warning Letter Analysis: Wellmill, LLC dba Vitamix Laboratories
**Company and Findings**
On April 20, 2026, the FDA's Human Foods Program issued a Warning Letter to Wellmill, LLC dba Vitamix Laboratories, a juice processing and dietary supplement manufacturing facility in Nesconset, New York. Following an inspection conducted December 3–12, 2025, the FDA determined that the company's juice products were adulterated and prepared under insanitary conditions. The facility blends ready-to-use juice with probiotic blends and packages the product without aseptic processing or subsequent pathogen reduction treatment.
**Regulatory Citations and Violations**
The primary violation concerns 21 CFR Part 120 (Juice HACCP regulation). The company failed to conduct an adequate written hazard analysis or develop an appropriate HACCP plan as required by 21 CFR 120.7(a) and 120.8(a). Specifically, the FDA cited three categories of unaddressed hazards: biological contamination from non-aseptic blending and bottling operations, bacterial growth and toxin formation from ambient temperature storage of products with pH above 3.7, and physical hazards from glass fragments in glass-bottled products. Additionally, the facility did not comply with 21 CFR 120.24(a), which mandates a minimum 5-log pathogen reduction process applied and final packaging within a single facility.
**Response Timeline and Industry Implications**
Wellmill received fifteen working days from April 20, 2026, to provide written corrective actions. The company submitted multiple responses between January and April 2026, ultimately stating it would discontinue marketing certain products as dietary supplements and revise labeling. However, the FDA noted that future dietary supplement marketing would trigger additional compliance obligations under 21 CFR Part 111. Peer compliance officers in juice processing should monitor whether Wellmill reformulates its processing methodology or faces enforcement action such as seizure or facility registration suspension.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Wellmill, LLC dba Vitamix Laboratories MARCS-CMS 725655 — April 20, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC DELIVERY Product: Food & Beverages Recipient: Recipient Name Michael W. Koschitz Recipient Title President Wellmill, LLC dba Vitamix Laboratories 106 Lake Ave S Suite 4-5 Nesconset , NY 11767 United States (b)(6), (b)(7)(C) Issuing Office: Human Foods Program United States April 20, 2026 WARNING LETTER Re: CMS 725655 Dear Mr. Koschitz: The United States Food and Drug Administration (FDA) inspected your juice processing and dietary supplement manufacturing facility, located at 106 Lake Ave S Suite 4-5, Nesconset, NY, from December 3, 2025, through December 12, 2025. During our inspection, the FDA investigator observed serious violations of the Juice Hazard Analysis and Critical Control Point (HACCP) regulation, Title 21, Code of Federal Regulations, Part 120 (21 CFR Part 120). Based on FDA's inspectional findings, we have determined that your (b)(4) and (b)(4) products are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. § 342(a)(4)) in that they have been prepared, packed, or held under insanitary conditions whereby they may have been rendered injurious to health. You may find the Act and the Juice HACCP regulation through links in FDA's home page at www.fda.gov. At the conclusion of the inspection, FDA issued a Form FDA 483 (FDA-483), Inspectional Observations, listing the deviations found at your facility. We received your responses to the FDA-483 on January 16, 2026, March 12, 2026, March 17, 2026, March 30, 2026, and April 6, 2026, describing corrective actions taken or planned by your firm. Your response also states that you will no longer manufacture and label (b)(4) products as dietary supplements and (b)(4) . Your April 6, 2026, response included revised labels for (b)(4) and (b)(4) reflecting this change. We acknowledge your statement that you no longer intend to market these products as dietary supplements and your provision of revised labels for (b)(4) and (b)(4) . However, should you market these or similar products in the future as dietary supplements, they would be subject to the Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements regulation, Title 21, Code of Federal Regulations, Part 111 (21 CFR Part 111), in addition to all other applicable regulatory requirements, including the juice HACCP regulations (21 CFR Part 120) as further discussed in this letter. Based on our review of the inspectional findings and your responses, we are issuing this letter to advise you of FDA’s continuing concerns and to provide detailed information describing the findings at your facility. Your significant violation is as follows: Juice HACCP (21 CFR Part 120) You must develop, or have developed for you, a written hazard analy…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What is the regulatory background for a CGMP — Current Good Manufacturing Practice warning letter?
- CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Wellmill, LLC dba Vitamix Laboratories had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Wellmill, LLC dba Vitamix Laboratories as of 2026-09-29. Argus ingests new FDA enforcement records daily.
- What FDA violations was Wellmill, LLC dba Vitamix Laboratories cited for?
- The FDA Warning Letter to Wellmill, LLC dba Vitamix Laboratories (issuing office: Human Foods Program) cites: Juice HACCP/CGMP for Foods/Adulterated/Insanitary Conditions. Classification: CGMP — Current Good Manufacturing Practice.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). 2026-04-20 FDA Warning Letter: Wellmill, LLC dba Vitamix Laboratories Cited for Juice HACCP/CGMP for Foods/Adulterated/Insanitary Conditions. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-wellmill-llc-dba-vitamix-laboratories-2026-04-20-cgmp
"2026-04-20 FDA Warning Letter: Wellmill, LLC dba Vitamix Laboratories Cited for Juice HACCP/CGMP for Foods/Adulterated/Insanitary Conditions." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-wellmill-llc-dba-vitamix-laboratories-2026-04-20-cgmp.
Argus HQ Research. "2026-04-20 FDA Warning Letter: Wellmill, LLC dba Vitamix Laboratories Cited for Juice HACCP/CGMP for Foods/Adulterated/Insanitary Conditions." Digital Empire Holdings LLC. Accessed September 30, 2026. https://argushq.ai/fda/warning-letter/fda-wl-wellmill-llc-dba-vitamix-laboratories-2026-04-20-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_wellmill_llc_dba_vitamix_laboratories_2026_04_20_cgmp_2026,
title = {2026-04-20 FDA Warning Letter: Wellmill, LLC dba Vitamix Laboratories Cited for Juice HACCP/CGMP for Foods/Adulterated/Insanitary Conditions},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-wellmill-llc-dba-vitamix-laboratories-2026-04-20-cgmp},
note = {Accessed: September 30, 2026}
}